Saturday - April 26, 2025

LOGIN  |  REGISTER
Assertio

AirSculpt Technologies Announces First Quarter 2023 Earnings Release Date and Conference Call

April 28, 2023 | Last Trade: US$1.96 0.14 7.69

MIAMI BEACH, Fla., April 28, 2023 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report first quarter 2023 financial results before market open on Friday, May 12, 2023, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.

The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13738277 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.elitebodysculpture.com. A replay of the webcast will be available for approximately 90 days.

About AirSculpt Technologies

AirSculpt Technologies (NASDAQ: AIRS) is an experienced, fast-growing national provider of body contouring procedures delivering a premium consumer experience under its brand, Elite Body Sculpture. At Elite Body Sculpture, we provide custom body contouring using our proprietary AirSculpt® method that removes unwanted fat in a minimally invasive procedure, producing dramatic results. It is our mission to generate the best results for our patients.

Investor Contact:

Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
investors@elitebodysculpture.com

Media Contact:

Stephanie Evans Greene
Chief Marketing Officer
AirSculpt Technologies, Inc.
sevansgreene@elitebodysculpture.com

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page